Anteris Technologies Global Corp.

09/29/2025 | Press release | Distributed by Public on 09/29/2025 09:00

Proxy Results (Form 8-K)

Item 5.07
Submission of Matters to a Vote of Security Holders

On September 29, 2025, Anteris Technologies Global Corp. (the "Company") held a special meeting of its stockholders (the "Special Meeting") at which a quorum was present. The matters listed below were submitted to a vote of the Company's stockholders at the Special Meeting through the solicitation of proxies. Detailed descriptions of the proposals are included in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on August 18, 2025 (the "Proxy Statement").

A total of 18,687,740 shares of the Company's common stock were present at the Special Meeting in person, by virtual attendance, or by proxy, which represents approximately 51.8% of the shares of common stock outstanding as of August 11, 2025, which was the record date for the Special Meeting.

Proposal 1. The ASX Waiver Proposal

The Company's stockholders approved ASX Limited's grant to the Company of a waiver from Australian Securities Exchange Listing Rule 7.1 to permit the Company to issue new securities without obtaining the approval of the Company's stockholders under ASX Listing Rule 7.1, and otherwise on the terms and conditions summarized in the Proxy Statement (the "ASX Waiver Proposal"). The final voting results are as follows:

Votes For
Votes Against
Abstentions
13,655,466
2,601,191
2,431,083

Proposal 2. The Adjournment Proposal

In connection with the Special Meeting, the Company's stockholders approved the proposal to approve the adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the ASX Waiver Proposal. No adjournment was necessary as Proposal 1 was approved. The final voting results are as follows:

Votes For
Votes Against
Abstentions
13,762,610
2,461,912
2,463,218

Item 8.01
Other Events

PARADIGM Trial Update

Patient enrollment in the Company's global pivotal registration trial (the "PARADIGM Trial"), initially expected in the third quarter 2025, is now anticipated to commence in the fourth quarter 2025.

Following the Investigational Device Exemption ("IDE") review, the Federal Drug Administration ("FDA") requested additional information, primarily related to bench testing, which the Company has now addressed in a formal response. The IDE submission incorporates both the clinical study protocol and the underlying technology package, which demonstrates the DurAVR® THV System has been appropriately developed and tested for use in the global pivotal trial.

In parallel, regulatory submissions to competent authorities in Europe are underway, highlighting the Company's commitment to advancing the PARADIGM Trial across multiple regions.

Anteris Technologies Global Corp. published this content on September 29, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on September 29, 2025 at 15:00 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]